Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 7 |
| List of Tables | 9 | 2 |
| List of Figures | 11 | 2 |
| Seasonal Influenza Vaccines Market in Top Seven Countries - Introduction | 13 | 1 |
| Seasonal Influenza Vaccine Market in Top Seven Countries - Market Overview | 14 | 9 |
| Production Cycle for Seasonal Influenza Vaccines | 14 | 1 |
| Seasonal Influenza Vaccine Market in Top Seven Countries | 15 | 1 |
| Vaccination Pattern | 15 | 1 |
| Population | 15 | 1 |
| Vaccination Coverage | 16 | 1 |
| Vaccination Coverage | 17 | 1 |
| Total Number of Doses | 18 | 1 |
| Total Revenue | 19 | 1 |
| Drivers and Restraints | 20 | 1 |
| Drivers | 20 | 1 |
| Threat of Pandemic Influenza | 20 | 1 |
| Emergence of Novel Production Technologies and Vaccines | 21 | 1 |
| Increase in Geriatric Population | 21 | 1 |
| Government Support for Vaccination | 21 | 1 |
| Restraints | 22 | 1 |
| Entry Barriers to the Seasonal Influenza Vaccine Market | 22 | 1 |
| Variable Demand | 22 | 1 |
| Perception of Influenza as Benign Disease in Children | 22 | 1 |
| Seasonal Influenza Vaccine Market in Top Seven Countries - Geographical Landscape | 23 | 50 |
| The US | 23 | 1 |
| Vaccination Pattern | 23 | 1 |
| Population | 23 | 1 |
| Vaccinated Population Coverage | 24 | 1 |
| Vaccination Coverage | 25 | 1 |
| Number of Doses per Person | 25 | 1 |
| Total Number of Doses | 26 | 1 |
| Dose Contribution | 27 | 1 |
| Number of Public and Private Doses | 27 | 1 |
| Vaccine Cost | 27 | 1 |
| Total Revenue | 28 | 1 |
| Drivers and Restraints | 29 | 1 |
| Drivers | 29 | 1 |
| Recommendations for Annual Seasonal Influenza Vaccination | 29 | 1 |
| Increasing Seasonal Influenza Awareness | 29 | 1 |
| Vaccination is More Convenient | 29 | 1 |
| Growing Elderly Population | 29 | 1 |
| Barriers | 30 | 1 |
| Low Contribution from the Government | 30 | 1 |
| High Price of Vaccine | 30 | 1 |
| The UK | 30 | 1 |
| Vaccination Pattern | 30 | 1 |
| Population | 30 | 2 |
| Vaccinated Coverage | 32 | 1 |
| Vaccination Coverage | 33 | 1 |
| Number of Doses per Person | 33 | 1 |
| Total Number of Doses | 34 | 1 |
| Dose Contribution | 35 | 1 |
| Number of Public and Private Doses | 35 | 1 |
| Vaccine Cost | 35 | 1 |
| Total Revenue | 36 | 1 |
| Drivers and Restraints | 37 | 1 |
| Drivers | 37 | 1 |
| Increasing Vaccination Coverage among Elderly Population | 37 | 1 |
| Government Support for Immunization | 37 | 1 |
| Restraint | 37 | 1 |
| Low Vaccination Coverage for Influenza in Children and Adults | 37 | 1 |
| France | 38 | 1 |
| Vaccination Pattern | 38 | 1 |
| Population | 38 | 1 |
| Vaccination Coverage | 39 | 1 |
| Vaccination Coverage | 40 | 1 |
| Number of Doses per Person | 40 | 1 |
| Total Number of Doses | 41 | 1 |
| Doses Contribution | 42 | 1 |
| Number of Public and Private Doses | 42 | 1 |
| Vaccine Cost | 42 | 1 |
| Total Revenue | 43 | 1 |
| Drivers and Restraints | 44 | 1 |
| Drivers | 44 | 1 |
| Government Support for Immunization | 44 | 1 |
| Low Price for the Vaccine | 44 | 1 |
| Restraints | 44 | 1 |
| Stagnant Vaccination Coverage | 44 | 1 |
| Italy | 45 | 1 |
| Vaccination Pattern | 45 | 1 |
| Population | 45 | 1 |
| Vaccination Coverage | 46 | 1 |
| Vaccination Coverage | 47 | 1 |
| Number of Doses per Person | 47 | 1 |
| Total Number of Doses | 48 | 1 |
| Dose Contribution | 49 | 1 |
| Number of Public and Private Doses | 49 | 1 |
| Vaccine Cost | 49 | 1 |
| Total Revenue | 50 | 1 |
| Drivers and Restraints | 51 | 1 |
| Drivers | 51 | 1 |
| Government Support for Immunization against Seasonal Influenza | 51 | 1 |
| Increasing Elderly Population | 51 | 1 |
| Restraints | 51 | 1 |
| Lack of Awareness Regarding Disease Severity and Immunization Benefits | 51 | 1 |
| Spain | 52 | 1 |
| Vaccination Pattern | 52 | 1 |
| Population | 52 | 1 |
| Vaccination Coverage | 53 | 1 |
| Vaccination Coverage | 54 | 1 |
| Number of Doses per Person | 54 | 1 |
| Total Number of Doses | 55 | 1 |
| Dose Contribution | 56 | 1 |
| Number of Public and Private Doses | 56 | 1 |
| Vaccine Cost | 56 | 1 |
| Total Revenue | 57 | 1 |
| Drivers and Restraints | 58 | 1 |
| Drivers | 58 | 1 |
| Government Support for Immunization | 58 | 1 |
| Increasing Elderly Population | 58 | 1 |
| Low Vaccine Cost | 58 | 1 |
| Restraints | 58 | 1 |
| Lack of Awareness Regarding Disease and Vaccination | 58 | 1 |
| Germany | 59 | 1 |
| Vaccination Pattern | 59 | 1 |
| Population | 59 | 1 |
| Vaccination Coverage | 60 | 1 |
| Vaccination Coverage | 61 | 1 |
| Number of Doses per Person | 61 | 1 |
| Total Number of Doses | 62 | 1 |
| Dose Contribution | 63 | 1 |
| Number of Public and Private Doses | 63 | 1 |
| Vaccine Cost | 63 | 1 |
| Total Revenue | 64 | 1 |
| Drivers and Restraints | 65 | 1 |
| Drivers | 65 | 1 |
| Government Support for Immunization against Seasonal Influenza | 65 | 1 |
| Recommendations by Healthcare Workers | 65 | 1 |
| Increasing Aging Population | 65 | 1 |
| Restraints | 65 | 1 |
| Low Vaccination Rates among Adults and Children | 65 | 1 |
| High Vaccine Cost | 66 | 1 |
| Japan | 66 | 1 |
| Vaccination Pattern | 66 | 1 |
| Population | 66 | 1 |
| Vaccinated Population Contribution | 67 | 1 |
| Vaccination Coverage | 68 | 1 |
| Number of Doses per Person | 68 | 1 |
| Total Number of Doses | 69 | 1 |
| Vaccine Cost | 70 | 1 |
| Total Revenue | 70 | 1 |
| Drivers and Restraints | 71 | 1 |
| Drivers | 71 | 1 |
| Influenza Immunization Program | 71 | 1 |
| Incidences of Pandemic Influenza | 71 | 1 |
| Rapidly Growing Elderly Population | 71 | 1 |
| Subsidized Immunization for the Elderly | 71 | 1 |
| Restraints | 72 | 1 |
| Non-reimbursement of Influenza Vaccination Costs | 72 | 1 |
| Limited Availability Period for Subsidized Vaccines | 72 | 1 |
| Lack of Scientific Studies Establishing Safety and Efficacy of Flu Vaccines in Japan | 72 | 1 |
| High Vaccine Cost | 72 | 1 |
| Seasonal Influenza Vaccine Market in Top Seven Countries - Regulatory Landscape | 73 | 6 |
| Registration Process and Regulations for Vaccines in the US | 73 | 2 |
| Registration Process and Regulations for Vaccines in the EU | 75 | 2 |
| Registration Process and Regulations for Vaccines in Japan | 77 | 2 |
| Seasonal Influenza Vaccine Market in Top Seven Countries - Pipeline Analysis | 79 | 4 |
| Summary | 79 | 1 |
| Research and Development Pipeline by Phase | 79 | 1 |
| Promising Vaccines under Clinical Development | 80 | 1 |
| Flu Q-QIV | 80 | 1 |
| Overview | 80 | 1 |
| Clinical Study Details | 80 | 1 |
| Optaflu | 81 | 1 |
| Overview | 81 | 1 |
| Clinical Study Details | 81 | 1 |
| Fluzone QIV | 81 | 1 |
| Overview | 81 | 1 |
| Clinical Study Details | 81 | 1 |
| FluBlok | 82 | 1 |
| Overview | 82 | 1 |
| Clinical Trial Details | 82 | 1 |
| Q-LAIV Flu Vac | 82 | 1 |
| Overview | 82 | 1 |
| Clinical Trial Details | 82 | 1 |
| Seasonal Influenza Vaccine Market in Top Seven Countries - Competitive Landscape | 83 | 6 |
| Market Share Analysis | 83 | 1 |
| Competitive Profiling | 84 | 1 |
| Sanofi Pasteur | 84 | 1 |
| Overview | 84 | 1 |
| Major Marketed Products | 84 | 1 |
| SWOT Analysis | 85 | 1 |
| GlaxoSmithKline | 85 | 1 |
| Overview | 85 | 1 |
| Major Marketed Products | 85 | 1 |
| SWOT Analysis | 86 | 1 |
| Novartis Vaccines | 86 | 1 |
| Overview | 86 | 1 |
| Major Marketed Products | 86 | 1 |
| SWOT Analysis | 87 | 1 |
| AstraZeneca | 88 | 1 |
| Overview | 88 | 1 |
| Major Marketed Products | 88 | 1 |
| SWOT Analysis | 88 | 1 |
| Seasonal Influenza Vaccine Market in Top Seven Countries - Strategic Consolidation | 89 | 13 |
| Overview | 89 | 1 |
| Segmentation by Deal Type | 89 | 1 |
| Segmentation by Year | 90 | 1 |
| Major Merger and Acquisition Deals, 2009 2012 | 91 | 1 |
| Intrexon Acquires Neugenesis | 91 | 1 |
| Grupo Ferrer Internacional Completes Acquisition of 50% Stake in Alentia Biotech from Laboratorios Farmaceuticos | 91 | 1 |
| Nexus Merges with HX Diagnostics | 91 | 1 |
| Mymetics Acquires Virosome Biologicals | 91 | 1 |
| Abbott Laboratories Acquires Solvay Pharmaceuticals | 91 | 1 |
| Nutri Pharma Acquires a Majority Stake in Bionor Immuno | 92 | 1 |
| Johnson &Johnson Acquires Crucell | 92 | 1 |
| VBI Vaccines Acquires Epixis | 92 | 1 |
| Sanofi Pasteur Acquires Remaining 50% Joint Venture Interest in Sanofi Pasteur-Daiichi Sankyo Vaccines | 92 | 1 |
| Segmentation by Geography | 93 | 1 |
| Segmentation by Year | 94 | 1 |
| Major Licensing Agreements, 2009 2012 | 95 | 1 |
| Baxter International Expands its Licensing Agreement with Takeda Pharma | 95 | 1 |
| AltraVax Enters into Licensing Agreement with Maxygen | 95 | 1 |
| iBio Enters into Licensing Agreement with G-Con | 95 | 1 |
| NasVax Extends its Research Agreement with Novartis | 96 | 1 |
| Protein Sciences Expands its Licensing Agreement with UMN Pharma for FluBlok and PanBlok | 96 | 1 |
| Segmentation by Geography | 96 | 1 |
| Segmentation by Year | 97 | 1 |
| Major Partnership Deals | 98 | 1 |
| Merck Enters into Agreement with CSL Biotherapies | 98 | 1 |
| GenVec Enters into an Agreement with SAIC-Frederick | 98 | 1 |
| UMN Pharma Enters into Co-Development Agreement with API | 98 | 1 |
| Daiichi Sankyo Forms Joint Venture with Kitasato Institute Research | 99 | 1 |
| Novartis International Enters into an Agreement with Synthetic Genomics Vaccines | 99 | 1 |
| PPD Enters into Collaboration Agreement with Southern Research Institute | 99 | 1 |
| Segmentation by Geography | 100 | 1 |
| Segmentation by Year | 101 | 1 |
| Seasonal Influenza Vaccine Market in Top Seven Countries - Appendix | 102 | 5 |
| Market Definitions | 102 | 1 |
| Abbreviations | 102 | 1 |
| Bibliography | 102 | 2 |
| Research Methodology | 104 | 2 |
| Secondary Research | 104 | 1 |
| Primary Research | 104 | 1 |
| Model for Estimation of Seasonal Influenza Vaccine Market | 104 | 2 |
| Geographical Landscape | 106 | 1 |
| Pipeline Analysis | 106 | 1 |
| Competitive Landscape | 106 | 1 |
| Strategic Consolidations | 106 | 1 |
| Contact Us | 106 | 1 |
| Disclaimer | 106 | 1 |